Compare BW & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BW | TVGN |
|---|---|---|
| Founded | 1867 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 21.3M |
| IPO Year | 2015 | 2021 |
| Metric | BW | TVGN |
|---|---|---|
| Price | $7.35 | $7.43 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 6.5K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.46 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,062,388,000.00 | N/A |
| Revenue This Year | $41.58 | N/A |
| Revenue Next Year | $66.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.64 | $0.14 |
| 52 Week High | $22.03 | $12.03 |
| Indicator | BW | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 68.02 |
| Support Level | $6.75 | $6.22 |
| Resistance Level | $8.05 | $7.90 |
| Average True Range (ATR) | 0.44 | 0.40 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 49.82 | 92.37 |
Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.